JTTT

10.3000.00%
JK

Jonathon Kluft

Independent Director

Dr. Jonathon Kluft, M.D., is Independent Director of JATT II Acquisition Corp. from April 16, 2026. He is Independent Director of JATT III Acquisition Corp. since August 25, 2026. He serves as a consultant to Atika Capital Management, LLC, a healthcare, consumer and technology-focused hedge fund and also engages in private investment activities. Dr. Kluft has experience in biotechnology investing and investment analysis across a broad range of therapeutic areas. From April 2016 to June 2025, Dr. Kluft served as Vice President, Special Projects and prior to that, Vice President, Investments (previously Business Development) at Roivant Sciences, where he was closely involved in the sourcing, evaluation and execution of transactions that resulted in the formation of several Roivant subsidiary companies, including Immunovant, Urovant and Pulmovant, among others. Prior to joining Roivant, from January 2013 through April 2016, Dr. Kluft was an Analyst at Atika Capital, where he identified and presented equity investment recommendations primarily within the pharmaceutical and biotechnology sectors. Earlier in his career, Dr. Kluft served as an intern at Gilder, Gagnon, Howe & Co., an asset management firm, where he conducted due diligence on biotechnology companies. His background in biotechnology investing provides the Board with valuable perspective in evaluating potential acquisition opportunities, drug development programs and strategic transactions. Dr. Kluft received his M.D. from Columbia University College of Physicians and Surgeons in 2013 and his B.A. in Philosophy, Politics and Economics from the University of Pennsylvania in 2005.

Positions